Skip to content
Screener

G&A at other companies

eXoZymes, Inc. logo
eXoZymes, Inc.EXOZ
$1.27M-8.0%
Sana Biotechnology logo
Sana BiotechnologySANA
$11.46M-0.2%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$6.77M+11.3%

Segments

By segment

See full
Reportable Segment$11.11M

Other financials

Income statement

See full
Revenue$20.2M-48.5%
Gross profit$18.4M-45.4%
Operating income-$58.5M-0.7%
Net income-$46.7M+22.5%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$172.0M-31.6%
Total debt$404.1M-5.8%
Total equity$420.3M-31.4%
Total assets$990.0M-19.6%

Cash flow

See full
Operating cash flow-$44.3M-10.0%
CapEx$2.6M+6,792%
Free cash flow-$46.9M-16.4%

Valuation

See full
Market cap$520.64M-26.0%
Enterprise value$752.73M-14.6%
P/S4.7×+1.3×

Profitability

See full
Gross margin91.8%
Operating margin-259.9%+1,304pp
Net margin-260%+718pp
FCF margin-156.3%+38.7pp

Returns & leverage

See full
Return on equity-56.3%+23.1pp
Debt / equity+0.3×
Current ratio4.6×-0.8×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054298
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Costs and operating expenses:
Cost of other revenue1,7195,3804,8179,470
Research and development46,21053,37096,130124,293
General and administrative30,77534,98168,60574,704
Restructuring charges3,5668,032
Total operating expenses78,70497,297169,552216,499
Loss from operations(58,548)(58,163)(129,922)(139,135)
Other income (expense):

Item 1. Financial Statements (Unaudited)

FAQ

What is Ginkgo Bioworks's G&A?
Ginkgo Bioworks (DNA) reported G&A of $30.78M in Q2 2026.
How has Ginkgo Bioworks's G&A changed year-over-year?
Ginkgo Bioworks's G&A decreased by 12.0% year-over-year, from $34.98M to $30.78M.
What is the long-term trend for Ginkgo Bioworks's G&A?
Over 4 years (2021 to 2025), Ginkgo Bioworks's G&A has grown at a -33.8% compound annual growth rate (CAGR), from $862.95M to $165.67M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Ginkgo Bioworks's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude